MAPK3 and neoplasm: Whether the same scenario takes place when p38 and ERK1/2 pathways are activated downstream of α3β1 in endothelial cells as a consequence of tumor/endothelial cell adhesion, and whether endothelial p38, ERK1/2, and MMPs could serve as molecular targets for anti-metastatic therapies could be of paramount interest.